Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Angioedema is characterized by the occurrence of transitory and recurrent subcutaneous and/or submucosal edemas resulting in swelling and/or abdominal pain.
Biomarker and diagnostic research for non-histaminic angioedema has been reported in the published literature.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
5 clinical trials registered, 4 recruiting. Interventions under study include other interventions, drug therapy, gene therapy, and biologic therapy. Pipeline includes 1 PHASE4, 1 PHASE1, 1 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06818474](https://clinicaltrials.gov/study/NCT06818474) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 1:57 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Lanadelumab in Long-term Prophylaxis of Acquired Angioedema |
PHASE4 |
Bernstein Clinical Research Center |
RECRUITING |
[NCT04597944](https://clinicaltrials.gov/study/NCT04597944) | Lanadelumab in Bradykinin Angioedema | — | University Hospital, Grenoble | UNKNOWN |
[NCT03845946](https://clinicaltrials.gov/study/NCT03845946) | CLOUD-R HAE REGISTRY | — | University Hospital, Grenoble | RECRUITING |
[NCT04334031](https://clinicaltrials.gov/study/NCT04334031) | Deployment o the Multidisciplinary Prospective Cohort Imminent | NA | University Hospital, Lille | RECRUITING |
[NCT07046806](https://clinicaltrials.gov/study/NCT07046806) | Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients | PHASE1 | Institute for Asthma and Allergy | RECRUITING |
111 publications have been identified in PubMed for non-histaminic angioedema. Research spans Review / Meta-Analysis (47%), Clinical Trial Publication (15%), and Case Report / Case Series (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 44 | 47% |
Clinical study results | 14 | 15% |
Patient case studies | 13 | 14% |
Disease patterns and progression | 11 | 12% |
Other research | 8 | 9% |
Laboratory research | 2 | 2% |
Testing and diagnosis research | 1 | 1% |
New treatment approaches | 1 | 1% |
Abdulkarim A (2026). [PMID: 29489144](https://pubmed.ncbi.nlm.nih.gov/29489144/). *Unknown Journal*. [Review / Meta-Analysis]
Regis J (2026). [PMID: 41860288](https://pubmed.ncbi.nlm.nih.gov/41860288/). *Cardiol Rev*. [Review / Meta-Analysis]
Long B (2026). [PMID: 40810708](https://pubmed.ncbi.nlm.nih.gov/40810708/). *Ann Emerg Med*. [Review / Meta-Analysis]
Bhattarai I (2026). [PMID: 41588789](https://pubmed.ncbi.nlm.nih.gov/41588789/). *Int J Rheum Dis*. [Other]
Syed YY (2026). [PMID: 41222832](https://pubmed.ncbi.nlm.nih.gov/41222832/). *Drugs*. [Review / Meta-Analysis]
Ito K (2025). [PMID: 39838162](https://pubmed.ncbi.nlm.nih.gov/39838162/). *Int J Hematol*. [Other]
Young MC (2025). [PMID: 40380367](https://pubmed.ncbi.nlm.nih.gov/40380367/). *Allergy Asthma Proc*. [Review / Meta-Analysis]
Carhart P (2025). [PMID: 40539179](https://pubmed.ncbi.nlm.nih.gov/40539179/). *Cureus*. [Case Report / Case Series]
Castaldo AJ (2025). [PMID: 40414286](https://pubmed.ncbi.nlm.nih.gov/40414286/). *Ann Allergy Asthma Immunol*. [Epidemiology / Natural History]
Levy DS (2025). [PMID: 40958183](https://pubmed.ncbi.nlm.nih.gov/40958183/). *Allergy Asthma Proc*. [Review / Meta-Analysis]